Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | FOXM1 | Q08050 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7135308 | 0.99 | KDM4E (0.81) | KDM4EALDH1A1KMT2AMEN1FOXM1 | |
| SCHEMBL2352175 | 0.88 | KDM4E (0.69) | KDM4EALDH1A1KMT2AMEN1FOXM1 | |
| SCHEMBL29045839 | 0.87 | FOXM1 (0.85) | KDM4EALDH1A1KMT2AMEN1FOXM1 | |
| SCHEMBL11876550 | 0.84 | KDM4E (0.58) | KDM4EALDH1A1KMT2AMEN1FOXM1 | |
| SCHEMBL23074698 | 0.83 | ALDH1A1 (0.70) | KDM4EALDH1A1KMT2AMEN1FOXM1 | |
| SCHEMBL12204135 | 0.83 | ALDH1A1 (0.70) | KDM4EALDH1A1KMT2AMEN1FOXM1 | |
| SCHEMBL29045824 | 0.83 | FOXM1 (0.95) | KDM4EALDH1A1KMT2AMEN1FOXM1 | |
| SCHEMBL11876541 | 0.83 | FOXM1 (0.59) | KDM4EALDH1A1KMT2AMEN1FOXM1 | |
| SCHEMBL5264483 | 0.82 | KDM4E (0.66) | KDM4EALDH1A1KMT2AMEN1FOXM1 | |
| SCHEMBL29045785 | 0.81 | FOXM1 (0.97) | KDM4EALDH1A1KMT2AMEN1FOXM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506876-B1 | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. | 2003-01-14 | — | — | US | disclosed |
| EP-0804427-B1 | LTA4 HYDROLASE INHIBITORS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1221441-A2 | LTA4 Hydrolase inhibitors | G.D. SEARLE & CO. (US) | 2002-07-10 | — | — | EP | disclosed |
| EP-0804427-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0786992-A2 | LTA 4? HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5585492-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES WHICH ARE MEDIATED BY LTB4 PRODUCTION, SUCH AS PSORIASIS, ULCERATIVE COLITIS, IRRITABLE BOWEL DISEASE AND ASTHMA | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |